Loading
A phase 3 trial testing YL201 in non-small-cell lung cancer, active and no longer recruiting.
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302） is a phase 3 interventional study registered as NCT06612151, led by MediLink Therapeutics (Suzhou), and active but no longer recruiting on the registry. Official title: A Multicenter, Randomised, Controlled, Open-label, Phase III Study to Compare the Efficacy and Safety of YL201 Versus Topotecan Hydrochloride in Subjects With Relapsed Small Cell Lung Cancer. Planned enrolment is 438 participants (estimated). The study started in 2024-12-17 and primary completion is expected in 2027-12-01. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares YL201, MediLink Therapeutics, Non-small-cell lung cancer.
Shares YL201, MediLink Therapeutics.
Shares YL201, MediLink Therapeutics.
Shares YL201, MediLink Therapeutics, Non-small-cell lung cancer.
Shares YL201, MediLink Therapeutics.
Shares YL201, MediLink Therapeutics.
Shares YL201, MediLink Therapeutics.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/